Cargando…

Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients

PURPOSE: Guiding response to neoadjuvant chemotherapy (guided-NACT) allows for an adaptative treatment approach likely to improve breast cancer survival. In this study, our primary aim is to explore the expected cost-effectiveness of guided-NACT using as a case study the first randomized controlled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miquel-Cases, Anna, Retèl, Valesca P., Lederer, Bianca, von Minckwitz, Gunter, Steuten, Lotte M. G., van Harten, Wim H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4849576/ https://www.ncbi.nlm.nih.gov/pubmed/27124410 http://dx.doi.org/10.1371/journal.pone.0154386

Ejemplares similares

Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands
por: Miquel-Cases, Anna, et al.
Publicado: (2016)

A cost-effectiveness analysis of a preventive exercise program for patients with advanced head and neck cancer treated with concomitant chemo-radiotherapy
por: Retèl, Valesca P, et al.
Publicado: (2011)

Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation
por: Retèl, Valesca P., et al.
Publicado: (2018)

Image-guided navigation for locally advanced primary and locally recurrent rectal cancer: evaluation of its early cost-effectiveness
por: Lindenberg, Melanie, et al.
Publicado: (2022)

PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
por: Guo, Sanxing, et al.
Publicado: (2020)

Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness
por: Lindenberg, Melanie, et al.
Publicado: (2020)

State of the art in neoadjuvant therapy of breast cancer
por: Minckwitz, Gunter von, et al.
Publicado: (2013)

Cost-utility analysis on robot-assisted and laparoscopic prostatectomy based on long-term functional outcomes
por: Lindenberg, Melanie A., et al.
Publicado: (2022)

Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis
por: van Amerongen, Rosa A, et al.
Publicado: (2016)

Early budget impact analysis on magnetic seed localization for non-palpable breast cancer surgery
por: Lindenberg, Melanie, et al.
Publicado: (2020)

Treating (low-risk) DCIS patients: What can we learn from real-world cancer registry evidence?
por: Byng, Danalyn, et al.
Publicado: (2021)

Developing a dynamic simulation model to support the nationwide implementation of whole genome sequencing in lung cancer
por: van de Ven, Michiel, et al.
Publicado: (2022)

Understanding the Costs of Surgery: A Bottom-Up Cost Analysis of Both a Hybrid Operating Room and Conventional Operating Room
por: Patel, Sejal, et al.
Publicado: (2020)

Recent advances in systemic therapy. Advances in neoadjuvant (primary) systemic therapy with cytotoxic agents
por: Untch, Michael, et al.
Publicado: (2009)

Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials
por: von Waldenfels, Gabriel, et al.
Publicado: (2018)

High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation
por: Verbeek, Joost G. E., et al.
Publicado: (2023)

Scenario drafting to anticipate future developments in technology assessment
por: Retèl, Valesca P, et al.
Publicado: (2012)

Affordable Prices Without Threatening the Oncological R&D Pipeline—An Economic Experiment on Transparency in Price Negotiations
por: Franzen, Nora, et al.
Publicado: (2022)

Cost-utility, cost-effectiveness, and budget impact of Internet-based cognitive behavioral therapy for breast cancer survivors with treatment-induced menopausal symptoms
por: Verbeek, Joost G. E., et al.
Publicado: (2019)

Association between genomic recurrence risk and well-being among breast cancer patients
por: Retèl, Valesca P, et al.
Publicado: (2013)

Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques
por: Heil, Joerg, et al.
Publicado: (2015)

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product
por: Lindenberg, Melanie A., et al.
Publicado: (2018)

Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy
por: Sinn, Bruno Valentin, et al.
Publicado: (2019)

Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy
por: Marinovich, M L, et al.
Publicado: (2013)

Cost-Effectiveness Analysis of a Procalcitonin-Guided Decision Algorithm for Antibiotic Stewardship Using Real-World U.S. Hospital Data
por: Voermans, Anne M., et al.
Publicado: (2019)

Return-to-work intervention for cancer survivors: budget impact and allocation of costs and returns in the Netherlands and six major EU-countries
por: Mewes, Janne C., et al.
Publicado: (2015)

Whole genome sequencing in oncology: using scenario drafting to explore future developments
por: van de Ven, Michiel, et al.
Publicado: (2021)

Study protocol of a prospective multicenter study comparing (cost-)effectiveness of a tailored interdisciplinary head and neck rehabilitation program to usual supportive care for patients treated with concomitant chemo- or bioradiotherapy
por: Beck, Ann-Jean C. C., et al.
Publicado: (2019)

Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
por: Darb-Esfahani, Silvia, et al.
Publicado: (2009)

Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto Trial
por: Issa-Nummer, Yasmin, et al.
Publicado: (2013)

Innovations that reach the patient: early health technology assessment and improving the chances of coverage and implementation
por: van Harten, WH, et al.
Publicado: (2016)

Close cooperation with Health Technology Assessment expertise is crucial for implementation and ultimately reimbursement of innovations in oncology
por: van Harten, WH, et al.
Publicado: (2016)

Cell-Free DNA at Diagnosis for Stage IV Non-Small Cell Lung Cancer: Costs, Time to Diagnosis and Clinical Relevance
por: Koole, Simone N., et al.
Publicado: (2022)

Evaluation of disease management programmes for chronically ill
por: Steuten, Lotte
Publicado: (2006)

Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis
por: Marinovich, Michael L., et al.
Publicado: (2015)

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer
por: Denkert, Carsten, et al.
Publicado: (2013)

The cost impact of PCT-guided antibiotic stewardship versus usual care for hospitalised patients with suspected sepsis or lower respiratory tract infections in the US: A health economic model analysis
por: Mewes, Janne C., et al.
Publicado: (2019)

DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis
por: Vici, Patrizia, et al.
Publicado: (2016)

Impact of Nuclear Oestrogen Receptor Beta Expression in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Heitz, Florian, et al.
Publicado: (2019)

Prospective cohort study using the breast cancer spheroid model as a predictor for response to neoadjuvant therapy – the SpheroNEO study
por: Halfter, Kathrin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_g6h5p8cmgbce6hrfrv427fu72v